Hope on the horizon: FDA approves eplontersen for hereditary transthyretin-mediated amyloidosis

被引:0
|
作者
Anwar, Insa Binte [1 ]
Ahmed, Iqra Furqan [1 ]
Mahmood, Fariha [1 ]
Haseeb, Abdul [2 ]
Ahmed, Khabab Abbasher Hussien Mohamed [3 ]
机构
[1] Liaquat Natl Med Coll, Karachi, Pakistan
[2] Jinnah Sindh Med Univ, Karachi, Pakistan
[3] Univ Khartoum, Fac Med, Khartoum 11111, Sudan
来源
ANNALS OF MEDICINE AND SURGERY | 2025年 / 87卷 / 01期
关键词
D O I
10.1097/MS9.0000000000002839
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:20 / 23
页数:4
相关论文
共 50 条
  • [21] Alnylam Act®: Heterogenous Disease Manifestations of Hereditary Transthyretin-Mediated Amyloidosis
    Malladi, Ruthvik
    Truty, Rebecca
    Winder, Tom
    Dinh, Quinn
    Melanson, Maria
    Agarwal, Sonalee
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S111 - S112
  • [22] Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
    Gertz, Morie A.
    Scheinberg, Morton
    Waddington-Cruz, Marcia
    Heitner, Stephen B.
    Karam, Chafic
    Drachman, Brian
    Khella, Sami
    Whelan, Carol
    Obici, Laura
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 701 - 711
  • [23] Hereditary Transthyretin-mediated Amyloidosis Masquerading as Diabetic Neuropathy and Lumbar Radiculopathy
    Horiuchi, K.
    Hortelano, C.
    Fogel, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 : S187 - S187
  • [24] Kidney Function And Proteinuria With Eplontersen Treatment For Hereditary Transthyretin Amyloidosis
    Maurer, Mathew s
    Gillmore, Julian D.
    Berk, John l
    Masri, Ahmad
    DA Silva, Moises dias
    Kwoh, Jesse
    Littl, Dustin j
    Natman, Jonatan
    Zhou, Wunan
    Waddington-cruz, Marcia
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01) : 346 - 347
  • [25] Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
    Dixon, Stacy
    Kang, Xuan
    Quan, Dianna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 973 - 981
  • [26] Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Garcia-Pavia, Pablo
    Grogan, Martha
    Kale, Parag
    Berk, John L.
    Maurer, Mathew S.
    Conceicao, Isabel
    Di Carli, Marcelo
    Solomon, Scott D.
    Chen, Chongshu
    Yureneva, Elena
    Vest, John
    Gillmore, Julian D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 397 - 410
  • [27] Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy
    Mueschen, Lars H.
    Koerner, Gudrun
    Gingele, Stefan
    Haenselmann, Anja
    Bavendiek, Udo
    Skripuletz, Thomas
    MUSCLE & NERVE, 2021, 64 (03) : E11 - E13
  • [28] Neurofilament light chain may serve as a biomarker in hereditary transthyretin-mediated amyloidosis
    Ticau, Simina
    Sridharan, Gautham
    Tsour, Shira
    Cantley, William
    Chan, Amy
    Gilbert, Jason
    Erbe, David
    Fitzgerald, Kevin
    Vaishnaw, Akshay
    Aldinc, Emre
    Nioi, Paul
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 530 - 531
  • [29] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
    Gonzalez-Duarte, Alejandra
    Judge, Daniel P.
    Dispenzieri, Angela
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Polydefkis, Michael
    NEUROLOGY, 2020, 94 (15)
  • [30] Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform (vol 271, pg 6655, 2024)
    Conceicao, Isabel
    Berk, John L.
    Weiler, Markus
    Kowacs, Pedro A.
    Dasgupta, Noel R.
    Khella, Sami
    Chao, Chi-Chao
    Attarian, Shahram
    Kwoh, T. Jesse
    Jung, Shiangtung W.
    Chen, Jersey
    Viney, Nicholas J.
    Yu, Rosie Z.
    Gertz, Morie
    Masri, Ahmad
    Cruz, Marcia Waddington
    Coelho, Teresa
    JOURNAL OF NEUROLOGY, 2025, 272 (02)